肝窦内皮细胞受体CLEC4M、stabilin-2和SCARA5在血栓形成与止血中对VWF-FVIII清除的贡献
本文综述肝窦内皮细胞受体CLEC4M、stabilin-2和SCARA5在调控血管性血友病因子(VWF)与凝血因子VIII(FVIII)清除中的作用。2010年CHARGE全基因组关联研究荟萃分析发现上述受体基因变异与正常个体血浆VWF和/或FVIII水平相关,后续体外与体内模型研究报道这些受体可结合、内化并清除VWF-FVIII复合物,患者研究描述了基因变异对1型血管性血友病/低VWF表型、FVIII药代动力学及静脉血栓栓塞风险的影响。
要点
- CHARGE全基因组关联研究荟萃分析发现CLEC4M、stabilin-2和SCARA5基因变异与正常个体血浆VWF和/或FVIII水平相关。
- 体外与体内模型研究报道上述受体可结合、内化并清除VWF-FVIII复合物。
- 患者研究描述了CLEC4M、STAB2和SCARA5基因变异对1型血管性血友病/低VWF表型、FVIII药代动力学及静脉血栓栓塞风险的影响。
核心结论
- 理解这些受体在调控VWF-FVIII清除中的作用,为调控血浆VWF和FVIII水平的基因组架构提供了重要见解,增进了对VWF-FVIII清除调节通路及定量VWF-FVIII病理机制基础的理解。
研究设计与样本
- 综述性文章,汇总2010年CHARGE全基因组关联研究荟萃分析、体外与体内模型研究以及患者研究的结果。
主要发现
- 2010年CHARGE全基因组关联研究荟萃分析在正常个体中识别出CLEC4M、stabilin-2和SCARA5基因变异与血浆VWF和/或FVIII水平相关。
- 使用体外和体内模型的一系列研究报道这些受体能够结合、内化并清除循环中的VWF-FVIII复合物。
- 在小鼠模型中,stabilin-2受体可调节对输注VWF-FVIII浓缩物的免疫反应。
- 多项患者研究描述了CLEC4M、STAB2和SCARA5基因变异对1型血管性血友病/低VWF表型、FVIII药代动力学及静脉血栓栓塞风险的影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quantitative abnormalities in factor VIII (FVIII) and its binding partner, von Willebrand factor (VWF), are associated with an increased risk of bleeding or thrombosis, and pathways that regulate the clearance of VWF-FVIII can strongly influence their plasma levels. In 2010, the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) on genome-wide association study meta-analysis identified variants in the genes for the sinusoidal endothelial receptors C-type lectin domain family 4 member M (CLEC4M), stabilin-2, and scavenger receptor class A member 5 (SCARA5) as being associated with plasma levels of VWF and/or FVIII in normal individuals. The ability of these receptors to bind, internalize, and clear the VWF-FVIII complex from the circulation has now been reported in a series of studies using in vitro and in vivo models. The receptor stabilin-2 has also been shown to modulate the immune response to infused VWF-FVIII concentrates in a murine model. In addition, the influence of genetic variants in CLEC4M, STAB2, and SCARA5 on type 1 von Willebrand disease/low VWF phenotype, FVIII pharmacokinetics, and the risk of venous thromboembolism has been described in a number of patient-based studies. Understanding the role of these receptors in the regulation of VWF-FVIII clearance has led to significant insights into the genomic architecture that modulates plasma VWF and FVIII levels, improving the understanding of pathways that regulate VWF-FVIII clearance and the mechanistic basis of quantitative VWF-FVIII pathologies.
引用
- Swystun LL, Michels A, Lillicrap D, et al. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis. J Thromb Haemost. 2023. PMID: 37085036. doi:10.1016/j.jtha.2023.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。